NCT07039799 The Effect of Virtual Reality Applications on Upper Extremity Functions in Patients With Duchenne Muscular Dystrophy
| NCT ID | NCT07039799 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University |
| Condition | Duchenne Muscular Dystrophy (DMD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2025-08-15 |
| Primary Completion | 2027-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2025-08-15 with a primary completion date of 2027-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effects of fully immersive virtual reality (VR) applications on upper extremity (UE) functions in individuals diagnosed with Duchenne Muscular Dystrophy (DMD). DMD is a progressive neuromuscular disorder that leads to muscle weakness and loss of function, including the upper limbs, which are essential for daily activities and independence. In this randomized controlled trial, 36 participants with DMD will be divided into two groups: a control group receiving conventional physiotherapy and an intervention group receiving the same physiotherapy program (excluding upper extremity exercises) combined with VR-based exercises. The VR games will be designed specifically to improve shoulder, elbow, wrist, and hand functions and will be delivered using Meta Quest 3 headsets with hand-tracking capabilities. Both groups will receive therapy twice a week for 8 weeks. Assessments will be conducted before and after the intervention, and at follow-up, using validated tools to measure UE function, grip strength, fine motor skills, trunk control, fatigue, quality of life, and participation in daily activities. The study aims to explore innovative rehabilitation strategies for DMD and contribute to improving the independence and quality of life of affected individuals.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of Duchenne Muscular Dystrophy (DMD) * Age ≥ 7 years * Ambulatory or non-ambulatory status (both are eligible) * Ability to follow movement instructions * Brooke Upper Extremity Functional Rating Scale (BUEFS) level ≤ 4 (i.e., able to bring hand to mouth) Exclusion Criteria: * Presence of any neurological diagnosis other than DMD * Cognitive, behavioral, or communication impairments that limit participation * Systemic illness or condition interfering with participation * Severe visual impairments incompatible with VR headset use * Presence of severe contractures or deformities that prevent execution of VR-based exercises
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07039799 clinical trial?
This trial is open to male participants only, aged 7 Years or older, up to 18 Years, studying Duchenne Muscular Dystrophy (DMD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07039799 currently recruiting?
Yes, NCT07039799 is actively recruiting participants. Contact the research team at csahrasirvan@gmail.com for enrollment information.
Where is the NCT07039799 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07039799 clinical trial?
NCT07039799 is sponsored by Istanbul University. The trial plans to enroll 36 participants.